Study on the expression and significance of Galectin-3 and CDC25B mRNA in human gastric carcinoma.
- Author:
Xiu-ming ZHANG
1
;
Gen-you YAO
;
Bu-yi ZHANG
;
Ling-ling WANG
;
Min ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Female; Galectin 3; genetics; metabolism; Gene Expression; genetics; Gene Expression Regulation, Neoplastic; Humans; Male; Prognosis; RNA, Messenger; metabolism; Stomach Neoplasms; genetics; metabolism; pathology; cdc25 Phosphatases; genetics; metabolism
- From: Chinese Journal of Medical Genetics 2009;26(3):288-292
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the expression of Galectin-3 and CDC25B mRNA in gastric carcinoma and their correlation with clinical-pathological features and the survival time.
METHODSTissue microarray (TMA) technique and in situ hybridization were used to detect the expression of Galectin-3 and CDC25B mRNA in 220 gastric carcinoma specimens and 31 normal gastric mucosa samples.
RESULTSIn situ hybridization results revealed that from the 220 cases, the positive expression rate of Galectin-3 and CDC25B mRNA were 58.6% and 54.1%, respectively. There was significant relationship between the Galectin-3 mRNA expression and tumor diameter, advanced TNM stage, invasion depth, vessel invasion, lymph node and distant metastasis. There was significant relationship between CDC25B mRNA expression and tumor diameter, advanced TNM stage, vessel invasion, lymph node and distant metastasis. In addition, there was apositive relationship of Galectin-3 and CDC25B mRNA expression. Finally, the mean survival time in cases with Galectin-3 and CDC25B mRNA positive expression was significantly shorter than those without Galectin-3 and CDC25B expression.
CONCLUSIONThe expression of Galectin-3 and CDC25B mRNA appears to act as a promoting factor in the onset and development of gastric cancer. It can be used as a marker of prognosis of gastric carcinoma in clinical practice.
